Spasticity

References

1. LANCE JW. WHAT IS SPASTICITY? LANCET 1990;335:606.

2. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007;68:326-37.

3. Traumatic brain injury. National Center for Injury Control and Prevention, 2008. (Accessed March 13, 2008, 2008, at http://www.cdc.gov/ncipc/tbi/TBI.htm.)

4. Yeargin-Allsopp M, Van Naarden Braun K, Doernberg NS, Benedict RE, Kirby RS, Durkin MS. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008;121:547-54.

5. Spinal cord injury. National Center for Injury Control and Prevention, 2008. (Accessed March 13, 2008, 2008, at http://www.cdc.gov/ncipc/factsheets/scifacts.htm.)

6. Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair 2003;17:66-70.

7. Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Mult Scler 1999;5:78-88.

8. Noreau L, Proulx P, Gagnon L, Drolet M, Laramee MT. Secondary impairments after spinal cord injury: a population-based study. Am J Phys Med Rehabil 2000;79:526-35.

9. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil 2002;16:515-22.

10. Welmer AK, von Arbin M, Widen Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis 2006;21:247-53.

11. Wichers MJ, Odding E, Stam HJ, van Nieuwenhuizen O. Clinical presentation, associated disorders and aetiological moments in Cerebral Palsy: a Dutch population-based study. Disabil Rehabil 2005;27:583-9.

12. Wedekind C, Lippert-Gruner M. Long-term outcome in severe traumatic brain injury is significantly influenced by brainstem involvement. Brain Inj 2005;19:681-4.

13. Thompson FJ, Parmer R, Reier PJ, Wang DC, Bose P. Scientific basis of spasticity: insights from a laboratory model. J Child Neurol 2001;16:2-9.

14. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 1997;6:S1-13.

15. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl 1997;6:S21-35.

16. Esquenazi A, Mayer NH. Instrumented assessment of muscle overactivity and spasticity with dynamic polyelectromyographic and motion analysis for treatment planning. Am J Phys Med Rehabil 2004;83:S19-29.

17. Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil 2006;28:899-907.

18. Hsieh JT, Wolfe DL, Miller WC, Curt A. Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord 2008;46:86-95.

19. Hsieh YW, Hsueh IP, Chou YT, Sheu CF, Hsieh CL, Kwakkel G. Development and validation of a short form of the Fugl-Meyer motor scale in patients with stroke. Stroke 2007;38:3052-4.

20. Cooper A, Musa IM, van Deursen R, Wiles CM. Electromyography characterization of stretch responses in hemiparetic stroke patients and their relationship with the Modified Ashworth scale. Clin Rehabil 2005;19:760-6.

21. Ertekin C, Bademkiran F, Tataroglu C, Aydogdu I, Karapinars N. Adductor T and H reflexes in humans. Muscle Nerve 2006;34:640-5.

22. Fleuren JF, Nederhand MJ, Hermens HJ. Influence of posture and muscle length on stretch reflex activity in poststroke patients with spasticity. Arch Phys Med Rehabil 2006;87:981-8.

23. Ghotbi N, Olyaei GR, Hadian MR, Ansari NN, Bagheri H. Is there any relationship between the Modified Ashworth Scale scores and alpha motoneuron excitability indicators? Electromyogr Clin Neurophysiol 2006;46:279-84.

24. Hoving MA, van Kranen-Mastenbroek VH, van Raak EP, et al. Placebo controlled utility and feasibility study of the H-reflex and flexor reflex in spastic children treated with intrathecal baclofen. Clin Neurophysiol 2006;117:1508-17.

25. Huang CY, Wang CH, Hwang IS. Characterization of the mechanical and neural components of spastic hypertonia with modified H reflex. J Electromyogr Kinesiol 2006;16:384-91.

26. van der Salm A, Veltink PH, Hermens HJ, Ijzerman MJ, Nene AV. Development of a new method for objective assessment of spasticity using full range passive movements. Arch Phys Med Rehabil 2005;86:1991-7.

27. Kim DY, Park CI, Chon JS, Ohn SH, Park TH, Bang IK. Biomechanical assessment with electromyography of post-stroke ankle plantar flexor spasticity. Yonsei Med J 2005;46:546-54.

28. Nance PW. Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12:889-905.

29. Lockley L. The role of the specialist physiotherapist in the management of spasticity. Way Ahead 2004;7:6-7.

30. Albany K. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Muscle Nerve Suppl 1997;6:S221-31.

31. Brunstrom JE. Clinical considerations in cerebral palsy and spasticity. J Child Neurol 2001;16:10-5.

32. Woo R. Spasticity: orthopedic perspective. J Child Neurol 2001;16:47-53.

33. Glanzman AM, Kim H, Swaminathan K, Beck T. Efficacy of botulinum toxin A, serial casting, and combined treatment for spastic equinus: a retrospective analysis. Dev Med Child Neurol 2004;46:807-11.

34. McNee AE, Will E, Lin JP, et al. The effect of serial casting on gait in children with cerebral palsy: preliminary results from a crossover trial. Gait Posture 2007;25:463-8.

35. On AY, Kirazli Y, Kismali B, Aksit R. Mechanisms of action of phenol block and botulinus toxin Type A in relieving spasticity: electrophysiologic investigation and follow-up. Am J Phys Med Rehabil 1999;78:344-9.

36. Childers MK. The importance of electromyographic guidance and electrical stimulation for injection of botulinum toxin. Phys Med Rehabil Clin N Am 2003;14:781-92.

37. Munchau A, Bahlke G, Allen PJ, et al. Polymyography combined with time-locked video recording (video EMG) for presurgical assessment of patients with cervical dystonia. Eur Neurol 2001;45:222-8.

38. Traba Lopez A, Esteban A. Botulinum toxin in motor disorders: practical considerations with emphasis on interventional neurophysiology. Neurophysiol Clin 2001;31:220-9.

39. Goldstein EM. Spasticity management: an overview. J Child Neurol 2001;16:16-23.

40. Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol 2003;18 Suppl 1:S50-66.

41. Koman LA, Mooney JF, 3rd, Smith BP. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol 1996;11 Suppl 1:S23-8.

42. Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol 2001;16:37-46.

43. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005;53:3-9.

44. Scholtes VA, Dallmeijer AJ, Knol DL, et al. Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol 2007;36:30-9.

45. Kong KH, Neo JJ, Chua KS. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil 2007;21:28-35.

46. Hawamdeh ZM, Ibrahim AI, Al-Qudah AA. Long-term effect of botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy. Eura Medicophys 2007.

47. Verrotti A, Greco R, Spalice A, Chiarelli F, Iannetti P. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006;34:1-6.

48. Truong DD, Jost WH. Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006;12:331-55.

49. Sheean G. Botulinum toxin treatment of adult spasticity : a benefit-risk assessment. Drug Saf 2006;29:31-48.

50. Satila H, Kotamaki A, Koivikko M, Autti-Ramo I. Low- and high-dose botulinum toxin A treatment: a retrospective analysis. Pediatr Neurol 2006;34:285-90.

51. Satila H, Kotamaki A, Koivikko M, Autti-Ramo I. Upper limb function after botulinum toxin A treatment in cerebral palsy: two years follow-up of six cases. Pediatr Rehabil 2006;9:247-58.

52. Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007;29:683-90.

53. Pinder C, Bhakta B, Kodavali K. Intrathecal phenol: an old treatment revisited. Disabil Rehabil 2007:1-6.

54. Kwon JY, Kim JS. Selective Blocking of the Anterior Branch of the Obturator Nerve in Children with Cerebral Palsy. Am J Phys Med Rehabil 2007.

55. Tizanidine. Drugdex. In: Thomson Micromedex; 2008.

56. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364-73.

57. Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 2001;16:31-6.

58. Mathew A, Mathew MC, Thomas M, Antonisamy B. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005;51:109-13.

59. Cendrowski W, Sobczyk W. Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol 1977;16:257-62.

60. Kamen L, Henney HR, 3rd, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008;24:425-39.

61. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998;15:241-51.

62. Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. J Child Neurol 2006;21:1090-2.

63. Baclofen. Drugdex. In: Thomson Micromedex; 2008.

64. Boop FA, Woo R, Maria BL. Consensus statement on the surgical management of spasticity related to cerebral palsy. J Child Neurol 2001;16:68-9.

65. Pierson SH. Outcome measures in spasticity management. Muscle Nerve Suppl 1997;6:S36-60.